Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Updated Results from the German Mpnsg-0212 Combination Trial: Ruxolitinib Plus Pomalidomide in Myelofibrosis with Anemia

Blood (2019) 134 (Supplement_1): 672.

https://doi.org/10.1182/blood-2019-127859

Published: 2019

Journal Articles

Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy

Blood (2019) 134 (Supplement_1): 2950.

https://doi.org/10.1182/blood-2019-126035

Published: 2019

Journal Articles

Comparison of RNA-Based Versus DNA-Based Quantitative KIT D816V Mutation Analysis Reveals Significant Disparity in Patients with Advanced Systemic Mastocytosis

Mohamad Jawhar, Nicole Naumann, Johannes Lübke, Juliana Schwaab, Oliver Hofmann, Thomas Kielsgaard Kristensen, Karl Sotlar, Verena Haselmann, Sven Schneider, Georgia Metzgeroth, Henning D. Popp, Alice Fabarius, PhD, Peter Bugert, Wolf-Karsten Hofmann, MD PhD, Andreas Reiter

Blood (2019) 134 (Supplement_1): 2955.

https://doi.org/10.1182/blood-2019-128811

Published: 2019

Journal Articles

An Increased Bone Mineral Density As an Adverse Prognostic Factor in Patients with Systemic Mastocytosis

Mohamad Jawhar, Juliana Schwaab, Nicole Naumann, Georgia Metzgeroth, Alice Fabarius, PhD, Stefan O Schoenberg, Wolf-Karsten Hofmann, MD PhD, Philipp Riffel, Andreas Reiter

Blood (2019) 134 (Supplement_1): 4185.

https://doi.org/10.1182/blood-2019-129798

Published: 2019

Journal Articles

A New Prognostic Score for Advanced Systemic Mastocytosis Based on Clinical and Genetic Characteristics of 210 Consecutive Patients

Mohamad Jawhar, Juliana Schwaab, Nicole Naumann, Georgia Metzgeroth, MD, Hans-Peter Horny, Karl Sotlar, Manja Meggendorfer, PhD, Torsten Haferlach, MD, Nicholas C.P. Cross, Alice Fabarius, Wolf-Karsten Hofmann, Peter Valent, Andreas Reiter, MD

Blood (2018) 132 (Supplement 1): 349.

https://doi.org/10.1182/blood-2018-99-115804

Published: 2018

Journal Articles

Interim Results from Fight-203, a Phase 2, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Pemigatinib (INCB054828) in Patients with Myeloid/Lymphoid Neoplasms with Rearrangement of Fibroblast Growth Factor Receptor 1 ( FGFR1 )

Srdan Verstovsek, MD PhD, Alessandro M. Vannucchi, MD, Alessandro Rambaldi, MD PhD, Jason R. Gotlib, MDMS, Adam J. Mead, MD PhD, Andreas Hochhaus, MD, Jean-Jacques Kiladjian, MD PhD, Juan Carlos Hernandez Boluda, MD PhD, Ekaterine Asatiani, MD, Christine Lihou, BS, Huiling Zhen, MD PhD, Andreas Reiter, MD

Blood (2018) 132 (Supplement 1): 690.

https://doi.org/10.1182/blood-2018-99-110388

Published: 2018

Journal Articles

Eosinophil Differentiation and Viability in Hypereosinophilia Is Impaired By Genetic and Pharmacologic Targeting of LCP1 and PKC Beta

Guangxin Ma, Deniz Gezer, MD, Oliver Herrmann, Msc, Andreas Reiter, MD, Mohamad Jawhar, Mirle Schemionek, Tim H. Brümmendorf, MD, Steffen Koschmieder, MD, Nicolas Chatain, PhD

Blood (2018) 132 (Supplement 1): 4320.

https://doi.org/10.1182/blood-2018-99-114646

Published: 2018

Journal Articles

The CDK4/6 Inhibitor Palbociclib Exerts Growth-Inhibitory Effects on Neoplastic Mast Cells and Synergizes with Midostaurin in Producing Growth Arrest

Mathias A. Schneeweiss, Gabriele Stefanzl, Daniela Berger, Gregor Eisenwort, Mohamad Jawhar, Greiner Georg, MD PhD, Gregor Hoermann, Wolfgang R. Sperr, Michel Arock, Andreas Reiter, MD, Peter Valent, Karoline V. Gleixner, MD

Blood (2018) 132 (Supplement 1): 1363.

https://doi.org/10.1182/blood-2018-99-116525

Published: 2018

Journal Articles

Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels

John Mascarenhas, MD, Rami S. Komrokji, MD, Michele Cavo, MD, Bruno Martino, MD, Dietger Niederwieser, MD, Andreas Reiter, MD, Bart L Scott, MD, Maria R. Baer, MD, Ronald Hoffman, MD, Olatoyosi Odenike, MD, Jacqueline Bussolari, PhD, Eugene Zhu, PhD, Fei Huang, PhD, Esther Rose, MD, Laurie Sherman, BSN, Souria Dougherty, BS, MBA, Faye M. Feller, MD, Jean-Jacques Kiladjian, MD PhD

Blood (2018) 132 (Supplement 1): 685.

https://doi.org/10.1182/blood-2018-99-115163

Published: 2018

Journal Articles

Acquired Thrombotic Thrombocytopenic Purpura and Acute Pancreatitis: Variable and Reciprocal Pathophysiologic Relationships

Qian Qin, MD, Cesar Gentille Sanchez, MD, Xinyu Nan, MD, Lawrence Rice, MDBA

Blood (2017) 130 (Supplement 1): 3637.

https://doi.org/10.1182/blood.V130.Suppl_1.3637.3637

Published: 2017

Journal Articles

Molecular Profiling of Myeloid Progenitor Cells in Multi-Mutated Advanced Systemic Mastocytosis Identifies KIT D816V As a Distinct and Late Event

Mohamad Jawhar, MD, Juliana Schwaab, MD, Susanne Schnittger, PhD, Karl Sotlar, MD, Hans Peter Horny, MD, Georgia Metzgeroth, Sven Schneider, MD, Nadine Müller, Nicole Naumann, Christoph Walz, MD, Torsten Haferlach, Peter Valent, MD, Wolf-Karsten Hofmann, MD, Nicholas C.P. Cross, PhD, Alice Fabarius, PhD, Andreas Reiter, MD

Blood (2014) 124 (21): 3216.

https://doi.org/10.1182/blood.V124.21.3216.3216

Published: 2014

Journal Articles

Midostaurin (PKC412) Demonstrates a High Rate of Durable Responses in Patients with Advanced Systemic Mastocytosis: Results from the Fully Accrued Global Phase 2 CPKC412D2201 Trial

Jason Gotlib, MD MS, Hanneke C. Kluin-Nelemans, MD PhD, Tracy I. George, MD, Cem Akin, MD PhD, Karl Sotlar, MD, Olivier Hermine, MD PhD, Farrukh Awan, MD MS, Elizabeth O Hexner, MD, Michael Mauro, MD, David Sternberg, MD PhD, Matthieu Villeneuve, Fabienne Emery-Salbert, MSc, Eric Stanek, PharmD, Karin Hartmann, MD, Hans-Peter Horny, MD, Peter Valent, MD, Andreas Reiter, MD

Blood (2014) 124 (21): 636.

https://doi.org/10.1182/blood.V124.21.636.636

Published: 2014

Journal Articles

Molecular Characterization Of Myelofibrosis Patients With Cytopenia Treated With Pomalidomide: Results From The Mpnsg 01-09 Study

Frank Stegelmann, MD, Maximilian Laaths, MD, Andreas Reiter, MD, Edgar Jost, Martin Griesshammer, MD, PhD, Norbert Gattermann, MD, Holger Hebart, Cornelius F. Waller, MD, Philippe Schafhausen, MD, Uwe Platzbecker, MD, PhD, Andreas Hochhaus, MD, Walter Verbeek, MD, Igor W. Blau, MD, Carmen Blersch, Susanne Kuhn, Hartmut Döhner, MD, Richard F. Schlenk, MD, Konstanze Döhner, MD

Blood (2013) 122 (21): 4064.

https://doi.org/10.1182/blood.V122.21.4064.4064

Published: 2013

Journal Articles

Identification Of The Ki-1 Antigen (CD30) As a Novel Marker and Potential Therapeutic Target In Neoplastic Mast Cells In Advanced Systemic Mastocytosis

Katharina Blatt, MSc, Ph.D., Sabine Cerny-Reiterer, D.V.M, Karl Sotlar, M.D., Schwaab Juliana, M.D., Gregor Hoermann, M.D., Ph.D., Matthias Mayerhofer, M.D., Emir Hadzijusufovic, DVM, Michael Willmann, D.V.M., Andreas Reiter, MD, Hans-Peter Horny, MD, Peter Valent

Blood (2013) 122 (21): 3773.

https://doi.org/10.1182/blood.V122.21.3773.3773

Published: 2013

Journal Articles

Pomalidomide In MPN–associated Myelofibrosis With Cytopenia: Results Of The Mpnsg 01-09 Study

Blood (2013) 122 (21): 2822.

https://doi.org/10.1182/blood.V122.21.2822.2822

Published: 2013

Journal Articles

Durable Responses and Improved Quality Of Life With Midostaurin (PKC412) In Advanced Systemic Mastocytosis (SM): Updated Stage 1 Results Of The Global D2201 Trial

Jason Gotlib, MD, Hanneke C. Kluin-Nelemans, MD, PhD, Tracy I. George, MD, Cem Akin, MD, PhD, Karl Sotlar, MD, Olivier Hermine, Farrukh Awan, MD, MS, Elizabeth Hexner, MD, Michael Mauro, MD, Rodica Morariu, MD, Margaret Squier, MD, PhD, Matthieu Villeneuve, Fabienne Emery-Salbert, MSc, John Coombs, PharmD, MBA, Karin Hartmann, MD, Hans-Peter Horny, MD, Peter Valent, MD, Andreas Reiter, MD

Blood (2013) 122 (21): 106.

https://doi.org/10.1182/blood.V122.21.106.106

Published: 2013

Journal Articles

Efficacy and Safety Of Fedratinib (SAR302503/TG101348) In Patients With Intermediate- Or High-Risk Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Or Post-Essential Thrombocythemia (ET) MF Previously Treated With Ruxolitinib: Interim Results From a Phase II Study (JAKARTA-2)

Blood (2013) 122 (21): 661.

https://doi.org/10.1182/blood.V122.21.661.661

Published: 2013

Journal Articles

Influence Of Inhaled Nitric Oxide On Stored Red Blood Cell autotransfusion In Overweight Volunteers With Endothelial Dysfunction: Preliminary Results

Lorenzo Berra, Riccardo Pinciroli, MD, Binglan Yu, PhD, Christopher P. Stowell, MD, PhD, Kenneth D. Bloch, MD, Warren M. Zapol, MD

Blood (2013) 122 (21): 790.

https://doi.org/10.1182/blood.V122.21.790.790

Published: 2013

Journal Articles

Treatment of Primary Bone Lymphoma with Intensive Chemotherapy

Anna Morozova, Eugene Zvonkov, Vasilii Mamonov, Alla M. Kovrigina, MD, PhD, Sergei Kravchenko, Yuri Lorie, Vladimir I. Vorobyev, MD, Ekaterina Penskaya, Eduard Gemdjian, Valeriy G Savchenko, MD, PhD

Blood (2012) 120 (21): 4874.

https://doi.org/10.1182/blood.V120.21.4874.4874

Published: 2012

Journal Articles

PCM1-JAK2 Fusion Product Selectively Activates MAP-Kinase Pathway and Fails to Phosphorylate JAK2 and STAT5: Implications for Therapeutic Strategies.

Elena Masselli, MD, Cristina Mecucci, Giuliana Gobbi, PhD, Cecilia Carubbi, Sabrina Bonomini, Lucia Prezioso, MD, Elena Rossetti, MD, Cecilia Caramatti, MD, Marco Vitale, MD, Franco Aversa, MD

Blood (2012) 120 (21): 2858.

https://doi.org/10.1182/blood.V120.21.2858.2858

Published: 2012

NARROW

Updated Results from the German Mpnsg-0212 Combination Trial: Ruxolitinib Plus Pomalidomide in Myelofibrosis with Anemia

Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy

Comparison of RNA-Based Versus DNA-Based Quantitative KIT D816V Mutation Analysis Reveals Significant Disparity in Patients with Advanced Systemic Mastocytosis

An Increased Bone Mineral Density As an Adverse Prognostic Factor in Patients with Systemic Mastocytosis

A New Prognostic Score for Advanced Systemic Mastocytosis Based on Clinical and Genetic Characteristics of 210 Consecutive Patients

Interim Results from Fight-203, a Phase 2, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Pemigatinib (INCB054828) in Patients with Myeloid/Lymphoid Neoplasms with Rearrangement of Fibroblast Growth Factor Receptor 1 ( FGFR1 )

Eosinophil Differentiation and Viability in Hypereosinophilia Is Impaired By Genetic and Pharmacologic Targeting of LCP1 and PKC Beta

The CDK4/6 Inhibitor Palbociclib Exerts Growth-Inhibitory Effects on Neoplastic Mast Cells and Synergizes with Midostaurin in Producing Growth Arrest

Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels

Acquired Thrombotic Thrombocytopenic Purpura and Acute Pancreatitis: Variable and Reciprocal Pathophysiologic Relationships

Molecular Profiling of Myeloid Progenitor Cells in Multi-Mutated Advanced Systemic Mastocytosis Identifies KIT D816V As a Distinct and Late Event

Midostaurin (PKC412) Demonstrates a High Rate of Durable Responses in Patients with Advanced Systemic Mastocytosis: Results from the Fully Accrued Global Phase 2 CPKC412D2201 Trial

Molecular Characterization Of Myelofibrosis Patients With Cytopenia Treated With Pomalidomide: Results From The Mpnsg 01-09 Study

Identification Of The Ki-1 Antigen (CD30) As a Novel Marker and Potential Therapeutic Target In Neoplastic Mast Cells In Advanced Systemic Mastocytosis

Pomalidomide In MPN–associated Myelofibrosis With Cytopenia: Results Of The Mpnsg 01-09 Study

Durable Responses and Improved Quality Of Life With Midostaurin (PKC412) In Advanced Systemic Mastocytosis (SM): Updated Stage 1 Results Of The Global D2201 Trial

Efficacy and Safety Of Fedratinib (SAR302503/TG101348) In Patients With Intermediate- Or High-Risk Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Or Post-Essential Thrombocythemia (ET) MF Previously Treated With Ruxolitinib: Interim Results From a Phase II Study (JAKARTA-2)

Influence Of Inhaled Nitric Oxide On Stored Red Blood Cell autotransfusion In Overweight Volunteers With Endothelial Dysfunction: Preliminary Results

Treatment of Primary Bone Lymphoma with Intensive Chemotherapy

PCM1-JAK2 Fusion Product Selectively Activates MAP-Kinase Pathway and Fails to Phosphorylate JAK2 and STAT5: Implications for Therapeutic Strategies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only